Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike

Rhea-AI Filing Summary

Milestone Pharmaceuticals director Seth H. Z. Fischer received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if he continues serving.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fischer Seth H. Z.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	77,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 77,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 77,000 options Exercise price: $1.22 per share Expiration date: June 10, 2036 +2 more

5 metrics

Options granted 77,000 options Stock Option (right to buy) grant on June 10, 2026

Exercise price $1.22 per share Conversion or exercise price for the options

Expiration date June 10, 2036 Option term for the 77,000 options

Underlying shares 77,000 shares Common stock underlying the option grant

Post-grant derivative holdings 77,000 options Total stock options held directly after the transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"This option will vest in twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the stockholders financial

"fully vested on the date of next annual meeting of the stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fischer Seth H. Z.

(Last) (First) (Middle)

C/O MILESTONE PHARMACEUTICALS INC.

1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)

MONTREAL H4M 2X6

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.22	06/10/2026		A		77,000		(1)	06/10/2036	Common Stock	77,000	$0	77,000	D

Explanation of Responses:

1. This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

	/s/ Joseph Oliveto, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Milestone Pharmaceuticals (MIST) director Seth H. Z. Fischer report on this Form 4?

Seth H. Z. Fischer reported receiving a grant of stock options for 77,000 shares of Milestone Pharmaceuticals common stock. These options are compensation-related and were awarded at an exercise price of $1.22 per share, with vesting tied to his continued service on the board.

What are the key terms of the Milestone Pharmaceuticals (MIST) option grant to Seth H. Z. Fischer?

The grant covers 77,000 stock options with an exercise price of $1.22 per share and an expiration date of June 10, 2036. The options relate to Milestone Pharmaceuticals common stock and represent a right to buy shares rather than an immediate stock purchase.

How do the 77,000 Milestone Pharmaceuticals (MIST) options granted to Seth H. Z. Fischer vest?

The 77,000 options vest in twelve equal monthly installments beginning July 10, 2026. They will in any case be fully vested by the date of the next annual stockholders’ meeting, provided Fischer continues to provide service through each applicable vesting date.

Is the Milestone Pharmaceuticals (MIST) Form 4 transaction an open-market buy or sell?

The Form 4 reflects a compensation-related grant of stock options, not an open-market buy or sell transaction. The options were awarded at an exercise price of $1.22 per share and give Fischer the right to purchase Milestone Pharmaceuticals common stock in the future.

What is Seth H. Z. Fischer’s reported option position in Milestone Pharmaceuticals (MIST) after this grant?

After this grant, Fischer is reported to hold 77,000 stock options directly. Each option is exercisable into one share of Milestone Pharmaceuticals common stock at $1.22 per share, with an expiration date of June 10, 2036, subject to the stated vesting schedule.